Listen

Description

👉 Come see me in clinic:

https://www.sacomplete.com/

đź’Ś Sign up for my newsletter:

https://www.sacomplete.com/complete-medicine-blog

🎧 Listen to the Endocrine Matters podcast:

https://www.sacomplete.com/podcast

🎙️ Welcome to the Endocrine Matters podcast.

This podcast episode is sponsored by Complete Medicine and HeyHealthy.

Welcome back to Endocrine Matters. I’m your host, Dr. Arti Thangudu, board-certified endocrinologist, menopause society certified practitioner, and founder of Complete Medicine, where we care for high-achieving women living with obesity, prediabetes, diabetes, thyroid disease, and metabolic conditions.

In today’s episode, we’re doing something a little different—we’re bringing you inside a real endocrinology journal club, but in a way that’s practical, relatable, and meaningful whether you’re a clinician, trainee, or someone living with obesity or metabolic disease.

I’m joined by two incredible endocrinologists and colleagues, Dr. Vidhya Illuri and Dr. Munira Mehta, as we break down a major new study published in the New England Journal of Medicine on oral semaglutide for weight loss.

Together, we discuss:

If you’ve been hearing a lot about GLP-1 medications and wondering what’s real, what’s hype, and how this applies to everyday endocrine practice and patient safety, this episode is for you.

Our goal is to help you understand the science, the nuance, and the ethics behind prescribing powerful metabolic medications—so patients can get safe, effective, and compassionate care.

If you’d like support navigating weight loss medications, metabolic health, menopause, or complex endocrine care, we’d love to help you at Complete Medicine.

📍 Learn more about becoming a patient:

https://www.sacomplete.com/

📲 Follow along on Instagram: @drartithangudu

Thank you so much for listening and for supporting Endocrine Matters.